Back to search results

Remote Exercise for Gastroesophageal Cancer Survivors

This study is testing an individualized, supervised, remote exercise program for people who have survived early-stage (Stage I-III) esophageal, gastroesophageal junction, or gastric cancer. The goal is to see if this exercise program can improve physical function after aggressive cancer treatments. Participants will receive written instructions and videos of strengthening exercises. The study aims to see how many participants attend at least 80% of the exercise sessions and complete a final physical assessment. This trial is currently recruiting a small group of 20 participants.

Study design
This is an interventional study with a planned enrollment of 20 participants. The phase of the study is not specified.
What's involved
Participants will undergo blood sample collection and receive written instructions and videos for strengthening exercises. They will also complete a post-intervention functional assessment at 8 weeks.
Compensation
Not stated in the trial record.
Follow-up
Participants will be assessed at 8 weeks after starting the exercise intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07439484

Individually Tailored, Supervised, Remote Exercise Intervention to Improve Physical Function for Stage I-III Gastroesophageal Cancer Survivors, PRECISE Trial

Not Yet Recruiting
NAAges 18+InterventionalSupportive care
Jonsson Comprehensive Cancer Center
~20 participants
Updated 2026-05-11 on ClinicalTrials.gov
What's tested:ActigraphyBiospecimen CollectionEducational InterventionElectronic Health Record ReviewExercise InterventionInternet-Based Intervention

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of participants who attend at least 80% of the exercise sessions and complete the post-intervention functional assessment
Measured over At 8 weeks

Conditions

Clinical Stage I Esophageal Adenocarcinoma American Joint Committee on Cancer (AJCC) v8
Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8
Clinical Stage I Gastric Cancer AJCC v8
Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage II Esophageal Adenocarcinoma AJCC v8
Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8
Clinical Stage II Gastric Cancer AJCC v8
Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage III Esophageal Adenocarcinoma AJCC v8
Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8
Clinical Stage III Gastric Cancer AJCC v8
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8

Explore related trials

Esophageal CarcinomaGastric CarcinomaGastroesophageal Junction Adenocarcinoma

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Jingran Ji, MD · PRINCIPAL_INVESTIGATOR · UCLA / Jonsson Comprehensive Cancer Center

Who to contact

Jingran Ji, MD
[email protected]
310-829-5471
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults ≥ 18 years old at the start of study treatment
Diagnosis of early-stage (Stage I, II, III) esophageal, gastroesophageal junction, or gastric cancer. Histology can be adenocarcinoma, squamous cell carcinoma, or poorly differentiated carcinoma
Treated with at least one systemic therapy (chemotherapy or immunotherapy) and within 12 months of completing curative intent gastroesophageal cancer (GEC) treatment
Have evidence of physical function impairment, defined as a SPPB score of \< 12) at baseline
Ability to understand English and the willingness to sign a written informed consent document

Exclusion

Patients with stage I disease who underwent endoscopic resection or surgery alone without perioperative systemic therapy
Patients with stage IV disease or unresectable locally advanced disease taking a palliative treatment approach without a clearly defined end of treatment
Patients currently receiving ongoing systemic therapy for GEC or another malignancy
Patients who are unable to provide informed consent
Any other condition or pre-existing co-morbidity that would, in the Investigator's judgment, contraindicate the participation in the study due to safety concerns with study procedures
Currently participating in another exercise intervention research study seeking to improve functional status, alleviate frailty, muscle strength, exhaustion/fatigue, or cognitive function

What this trial measures

  • Percentage of participants who attend at least 80% of the exercise sessions and complete the post-intervention functional assessmentAt 8 weeks

    Will use descriptive statistics to summarize the participant population, feasibility metrics, and safety data. The study will be deemed feasible if \> 60% (12 or more) of the 20 enrolled participants are retained.